Meeting Banner
Abstract #1199

The multi-centre iBEAt study: A comprehensive multi-parametric MR imaging biomarker panel for Diabetic Kidney Disease

Kanishka Sharma1, Fotios Tagkalakis1, Irvin Teh2, Christopher Kelly2, David Shelley3, Virva Saunavaara4, Dmitry Kuznetsov5, Anil Karihaloo6, Michael Mansfield3, Mark Gilchrist7, Roberto De Blasi8, Mark Ibberson5, Maria-Alexandra Olaru9, Bernd Kühn9, Nicolas Grenier10, and Steven Sourbron1

1Leeds Imaging Biomarkers Group, Biomedical Imaging Science Department, LICAMM, University of Leeds, Leeds, United Kingdom, 2Biomedical Imaging Science Department, LICAMM, University of Leeds, Leeds, United Kingdom, 3University of Leeds, Leeds, United Kingdom, 4University of Turku, Turku, Finland, 5Swiss Institute of Bioinformatics, Lausanne, Switzerland, 6Novo Nordisk, Bagsværd, Denmark, 7University of Exeter, Exeter, United Kingdom, 8University of Bari, Bari, Italy, 9Siemens Healthcare GmbH, Erlangen, Germany, 10University of Bordeaux, Bordeaux, France

There is a major clinical need for better biomarkers to identify Diabetic Kidney Disease (DKD) patients at risk of progression. iBEAt is a prospective multi-centre cohort study in 500 patients aiming to determine if MRI biomarkers can provide prediction of progression. We have developed a dedicated MRI biomarker panel for iBEAt interrogating body composition, renal morphology and tissue structure, hemodynamics and filtration. Here we present the details as well as example data and preliminary results on the ISMRM/NIST phantom, and on healthy volunteers.

This abstract and the presentation materials are available to members only; a login is required.

Join Here